May 24, 2019 Last Updated 10:12 AM, May 22, 2019

Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic

Published in News
Read 481 times
Rate this item
(0 votes)

In this paper, published on Nature Communications by Simon Faissner and colleagues, the authors screened a group of 1040 compounds from the NINDS database in order to find a potential therapeutic compound for progressive multiple sclerosis, a diagnosis for which most of clinical trials have failed so far.


The authors narrowed down the initial group of 1040 molecules based on various criteria such as the ability to enter the CNS, to protect neuron cultures from iron- and rotenone-induced oxidative damage, or to influence T cell biology. The finally selected compound, clomipramine -a tricyclic antidepressant- was able to significantly ameliorate the clinical phenotype (age of onset and over-time severity) in both acute and chronical models of experimental autoimmune encephalomyelitis.

Source: Nature Communications

Last modified on Wednesday, 07 November 2018 10:33
Login to post comments

Registered area

Thanks to the support of
merck serono biogen sanofi

Conferences & Courses

17° Corso CRNI Viva la differenza: sesso e neuroimmunologia

March 7-10, 2018 
Bergamo - Bergamo Science Center


Encefaliti Autoimmuni e Malattie Demielinizzanti Atipiche

16 febbraio 2018
Aula Magna Giorgio De Sandre


JNIInternational Brain Research Organization
Bringing Neuroscience to the World
JNIJournal of Neuroimmunology
Studies on all branches of neurosciences covering both research and clinical problems of neuroscientific interest.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies. To find out more about the cookies we use and how to delete them, see our Cookie Policy